Celltrion

Celltrion is South Korea's largest biopharmaceutical company and a global pioneer in biosimilar development. The company developed the world's first antibody biosimilar (Remsima/Inflectra) and has built a portfolio of biosimilars for autoimmune diseases, oncology, and ophthalmology. Celltrion's vertically integrated model — from development through manufacturing to direct commercialization — has disrupted the traditional pharmaceutical value chain.

Celltrion has proven that Asian companies can compete with global pharma giants in complex biologic drug development, opening new markets for affordable biologics.